Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study
Authors' conclusion
While SGLT2i use has increased among people with T2D hospitalised with HF, uptake remains low. Optimising medication use at transitions from hospital to community care may ensure clinical benefits of these medicines are realised.
Study context
- Population
- Adults with T2D hospitalised with heart failure (HF), January 2014 to June 2021, New South Wales, Australia
- Participants
- 18,932 adults
- Outcome
- Quarterly trends in prevalence of SGLT2i use
Methodological detailslinked administrative data
- Linked administrative data
Main finding
As reported in the abstract
Prevalence of SGLT2i use · mid-2021
Increase in SGLT2i use
13-fold
SGLT2i use by mid-2021
13.2 %
Observational data: associations, not effects.
Further findings
Factors associated with SGLT2i use in 2020-2021
| aOR (95 % CI) | ||
|---|---|---|
| MalesHigher use | 1.49 (1.24–1.79) | |
| Primary diagnosis of HFHigher use | 1.21 (1.01–1.45) | |
| CKDLower use | 0.60 (0.48–0.75) | |
| 0.512Adjusted odds ratio (log scale) |
| Outcome | aOR (95 % CI) | |
|---|---|---|
| Factors associated with SGLT2i use in 2020-2021≥85 yearsvs 18-64 yearsLower use | 0.18 (0.12–0.26) | |
| 0.10.31310Adjusted odds ratio (log scale) |
Factors associated with SGLT2i use in 2020-2021
- Lower SGLT2i use with increasing clinical complexity (e.g. higher Charlson Score; frailty)
Original publication
Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study. Diabetes Res Clin Pract. Published 8 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →